▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #369 by analyst upside · 2026-09-16
ATHE
Alterity Therapeutics Limited
Healthcare · Market Cap $64M · P/E 0x
ANALYST PRICE TARGET
+278.6%
implied upside to consensus target
Current Price $3.5
Consensus Target $13.25
Bull Target $16.0
Bear Target $10.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
0
Sell
0
52-Week Low $2.66
52-Week High $5.89
YTD Return +10.8%
FUNDAMENTALS
Market Cap $64M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.88
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $4M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.66
52-Week High $5.89
Current Price $3.5
Bear Target $10.0
Bull Target $16.0
● Now $3.5 ● Target $13.25
TRADING DATA
Avg Volume 18K
YTD Return +10.8%
Analyst Count 4
Consensus Buy
Upside to Target +278.6%
Last Updated 2026-09-16

ANALYST SUMMARY

Alterity Therapeutics Limited (ATHE) is currently trading at $3.5 with a Wall Street consensus price target of $13.25, implying potential upside of 278.6% over the next 12 months. 4 analysts currently cover ATHE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.0, while the most cautious has a target of $10.0.

ATHE operates in the Healthcare sector with a market capitalisation of $64M. The stock is up 10.8% year-to-date and is currently trading near the lower end of its 52-week range of $2.66 – $5.89.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

SPRO +342.5%
Spero Therapeutics, Inc.
$66M · P/E 8.1x · Buy
FBIO +341.8%
Fortress Biotech, Inc.
$83M · P/E 0.9x · Buy
CCLD +198.8%
CareCloud, Inc.
$87M · P/E 29.3x · Buy
ATNM +180.0%
Actinium Pharmaceuticals, Inc.
$39M · P/E 3.7x · Buy
PLX +313.5%
Protalix BioTherapeutics, Inc.
$214M · P/E 11.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ATHE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Craig-Hallum ● Initiated
Buy 2026-08-11 Building track record
Jones Trading ● Initiated
Buy 2026-06-30 57% win rate (14 calls)
Canaccord Genuity ● Initiated
Speculative Buy 2025-12-17 Building track record
Maxim Group - Reiterated
Buy → Buy 2025-01-30 28% win rate (40 calls)
Maxim Group ● Initiated
Buy 2024-12-12 28% win rate (40 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →